CVS Health
Stock Forecast, Prediction & Price Target
CVS Health (CVS) stock Price Target by analysts
CVS Health (CVS) stock Price Target by analysts
Average Price Target
$71.33
Potential upside: 0.72%
CVS Health price prediction
What is CVS Health stock analysts` prediction?
CVS Health stock forecast: Based on 6 Wall Street analysts` predicted price targets for CVS Health in the last 3 months, the avarage price target is $71.33, with a high forecast of $NaN. The average price target represents a 0.72% change from the last price of $70.82.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
CVS Health stock Price Target by analysts
Full breakdown of analysts given CVS Health price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
George Hill Deutsche Bank | 0% 0/4 | 9 months ago | $66 -6.80% downside | $59.08 | StreetInsider | Previous targets (3) |
Stephen Baxter Wells Fargo | 0% 0/1 | 10 months ago | $66 -6.80% downside | $57.11 | StreetInsider | Previous targets (0) |
Ann Hynes Mizuho Securities | 0% 0/1 | 11 months ago | $66 -6.80% downside | $57.04 | StreetInsider | Previous targets (0) |
David MacDonald Truist Financial | 0% 0/3 | 11 months ago | $76 7.31% upside | $58.2 | Benzinga | Previous targets (2) |
Jessica Tassan Piper Sandler | 0% 0/2 | 11 months ago | $72 1.66% upside | $59.15 | StreetInsider | Previous targets (1) |
Andrew Mok Barclays | 0% 0/2 | 11 months ago | $82 15.78% upside | $66.63 | StreetInsider | Previous targets (1) |
George Hill Deutsche Bank | 0% 0/4 | about 1 year ago | $63 -11.04% downside | $57.85 | StreetInsider | Previous targets (3) |
Lisa Gill J.P. Morgan | 0% 0/1 | about 1 year ago | $86 21.43% upside | $58.58 | Benzinga | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/1 | about 1 year ago | $74 4.49% upside | $58.58 | Benzinga | Previous targets (0) |
Andrew Mok Barclays | 0% 0/2 | about 1 year ago | $65 -8.21% downside | $61.01 | TheFly | Previous targets (1) |
Anton Hie RBC Capital | 0% 0/1 | over 1 year ago | $68 -3.98% downside | $56.31 | StreetInsider | Previous targets (0) |
Jessica Tassan Piper Sandler | 0% 0/2 | over 1 year ago | $94 32.73% upside | $77.4 | StreetInsider | Previous targets (1) |
Erin Wright Morgan Stanley | 0% 0/1 | over 1 year ago | $100 41.20% upside | $73.76 | Benzinga | Previous targets (0) |
David MacDonald Truist Financial | 0% 0/3 | almost 2 years ago | $98 38.37% upside | $70.52 | Benzinga | Previous targets (2) |
Justin Lake Wolfe Research | 100% 2/2 | almost 2 years ago | $80 12.96% upside | $70.52 | StreetInsider | Previous targets (1) |
David MacDonald Truist Financial | 0% 0/3 | about 2 years ago | $103 45.43% upside | $71.27 | Benzinga | Previous targets (2) |
Unknown Morgan Stanley | N/A | over 2 years ago | $120 69.44% upside | $89.18 | Benzinga | N/A |
Unknown Evercore ISI | N/A | over 2 years ago | $100 41.20% upside | $93.19 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $101 42.61% upside | $92.91 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | almost 3 years ago | $119 68.03% upside | $100.22 | Benzinga | N/A |
Unknown Evercore ISI | N/A | almost 3 years ago | $125 76.50% upside | $100.52 | Benzinga | N/A |
Unknown Mizuho Securities | N/A | about 3 years ago | $120 69.44% upside | $106.39 | Benzinga | N/A |
George Hill Deutsche Bank | 0% 0/4 | about 3 years ago | $120 69.44% upside | $106.39 | Pulse 2.0 | Previous targets (3) |
Unknown Credit Suisse | N/A | about 3 years ago | $117 65.20% upside | $102.26 | Benzinga | N/A |
Unknown UBS | N/A | about 3 years ago | $127 79.32% upside | $103.14 | Benzinga | N/A |
Unknown Deutsche Bank | N/A | over 3 years ago | $113 59.55% upside | $97.73 | Benzinga | N/A |
Ivan Feinseth Tigress Financial | 0% 0/1 | over 3 years ago | $125 76.50% upside | $104.45 | Pulse 2.0 | Previous targets (0) |
George Hill Deutsche Bank | 0% 0/4 | over 3 years ago | $110 55.32% upside | $102.13 | Pulse 2.0 | Previous targets (3) |
Matt Borsch BMO Capital | 0% 0/1 | over 3 years ago | $120 69.44% upside | $104.24 | Pulse 2.0 | Previous targets (0) |
Ben Hendrix RBC Capital | 0% 0/1 | over 3 years ago | $119 68.03% upside | $104.79 | TipRanks Contributor | Previous targets (0) |
Nathan Rich Goldman Sachs | 0% 0/1 | over 3 years ago | $121 70.85% upside | $104.79 | StreetInsider | Previous targets (0) |
Brian Tanquilut Jefferies | 0% 0/1 | over 3 years ago | $120 69.44% upside | $102.39 | TipRanks Contributor | Previous targets (0) |
Michael Cherny Bank of America Securities | 0% 0/1 | over 3 years ago | $117 65.20% upside | $106.22 | Pulse 2.0 | Previous targets (0) |
Lance Wilkes Bernstein | 0% 0/1 | over 3 years ago | $116 63.79% upside | $105.48 | TheFly | Previous targets (0) |
Steve Baxter Wells Fargo | 0% 0/1 | over 3 years ago | $111 56.73% upside | $102.04 | TipRanks Contributor | Previous targets (0) |
David S Macdonald Truist Financial | 0% 0/1 | over 3 years ago | $124 75.09% upside | $105.25 | TheFly | Previous targets (0) |
Ricky Goldwasser Morgan Stanley | 0% 0/1 | over 3 years ago | $125 76.50% upside | $98.37 | TheFly | Previous targets (0) |
Charles Rhyee Cowen & Co. | 0% 0/1 | over 3 years ago | $114 60.97% upside | $98.33 | TheFly | Previous targets (0) |
A.J. Rice Credit Suisse | 0% 0/1 | over 3 years ago | $120 69.44% upside | $98.33 | TheFly | Previous targets (0) |
Joseph France Seaport Global | 100% 1/1 | almost 4 years ago | $110 55.32% upside | $88.31 | TheFly | Previous targets (0) |
Kevin Caliendo UBS | 100% 1/1 | almost 4 years ago | $106 49.67% upside | $93.71 | StreetInsider | Previous targets (0) |
Steven Halper Cantor Fitzgerald | 0% 0/1 | almost 4 years ago | $115 62.38% upside | $95.83 | StreetInsider | Previous targets (0) |
Justin Lake Wolfe Research | 100% 2/2 | over 4 years ago | $93 31.31% upside | $87.69 | TheFly | Previous targets (1) |
CVS Health Financial Estimates
CVS Health Revenue Estimates
CVS Health EBITDA Estimates
CVS Health Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $292.11B N/A | $322.46B 10.39% | $357.77B 10.94% | Avg: $387.19B Low: $380.59B High: $405.99B avg. 8.22% | Avg: $410.28B Low: $403.10B High: $423.22B avg. 5.96% | Avg: $433.61B Low: $426.02B High: $447.28B avg. 5.68% | Avg: $450.44B Low: $442.56B High: $464.64B avg. 3.88% |
Net Income
% change YoY
| $8.00B N/A | $4.31B -46.11% | $8.34B 93.55% | Avg: $8.69B Low: $6.72B High: $10.22B avg. 4.14% | Avg: $10.03B Low: $8.48B High: $15.11B avg. 15.50% | Avg: $12.55B Low: $12.26B High: $13.06B avg. 25.05% | Avg: $13.31B Low: $13.01B High: $13.85B avg. 6.05% |
EBITDA
% change YoY
| $19.67B N/A | $20.49B 4.17% | $18.19B -11.22% | Avg: $24.58B Low: $24.16B High: $25.77B avg. 35.08% | Avg: $26.04B Low: $25.59B High: $26.86B avg. 5.96% | Avg: $27.52B Low: $27.04B High: $28.39B avg. 5.68% | Avg: $28.59B Low: $28.09B High: $29.49B avg. 3.88% |
EPS
% change YoY
| $6 N/A | $3.29 -45.16% | $6.49 97.26% | Avg: $6.63 Low: $5.21 High: $7.93 avg. 2.16% | Avg: $7.71 Low: $6.58 High: $11.72 avg. 16.24% | Avg: $9.73 Low: $9.51 High: $10.13 avg. 26.24% | Avg: $10.32 Low: $10.09 High: $10.74 avg. 6.05% |
Operating Expenses
% change YoY
| $37.06B N/A | $38.21B 3.09% | $40.68B 6.47% | Avg: $47.43B Low: $46.62B High: $49.73B avg. 16.57% | Avg: $50.25B Low: $49.37B High: $51.84B avg. 5.96% | Avg: $53.11B Low: $52.18B High: $54.79B avg. 5.68% | Avg: $55.17B Low: $54.21B High: $56.91B avg. 3.88% |
FAQ
What is CVS Health stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 12.69% in 2025-2028.
We have gathered data from 17 analysts. Their low estimate is 6.72B, average is 8.69B and high is 10.22B.
What is CVS Health stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 5.93% in 2025-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $380.59B, average is $387.19B and high is $405.99B.
What is CVS Health stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 12.67% in 2025-2028.
We have gathered data from 17 analysts. Their low earnings per share estimate is $5.21, average is $6.63 and high is $7.93.
What is the best performing analyst?
In the last twelve months 6 analysts have been covering CVS Health stock. The most successful analyst is George Hill.